Author

admin

Browsing

Venezuelan President Nicolás Maduro’s wife arrived to court in New York City wearing bandages on her face and complaining of bruises on her ribs, according to her lawyer.

Her attorney, veteran prosecutor Mark Donnelly, told the court that Cilia Flores suffered ‘significant injuries’ when U.S. forces raided the couple’s compound in Caracas on Saturday. Donnelly requested that Flores receive a full X-ray to determine whether she fractured a rib in the incident.

Flores was already wearing two bandages on her face, one on her forehead and another above her eye.

Both she and her husband pleaded not guilty to narco-terrorism and other charges in their first appearance on Monday.

Maduro faces four charges: narco-terrorism conspiracy, cocaine importation conspiracy, possession of machine guns and destructive devices and conspiracy to possess machine guns and destructive devices.

Flores faces three charges, including cocaine importation conspiracy, possession of machine guns and destructive devices, and conspiracy to possess machine guns and destructive devices.

Donnelly filed a motion to serve as counsel for Flores earlier Monday. He previously served 12 years at the Department of Justice, including as senior advisor to the United States Attorney for the Southern District of Texas.

‘Mark has extensive experience investigating white collar cases, having run the Southern District’s fraud division for over two years. His white collar practice included FCPA investigations, Healthcare Fraud, joint SEC matters, large scale investor fraud, and cyber security matters,’ Donnelly’s biography on the website for the Parker Sanchez & Donnelly law firm reads.

The Texas House of Representatives also enlisted Donnelly to assist in the 2023 investigation and impeachment trial for Texas Attorney General Ken Paxton. Paxton’s impeachment case made it to the Texas Senate, but he was ultimately acquitted on all charges.

Maduro and Flores, who have been married for 12 years, were first introduced while working closely with Maduro’s predecessor, Hugo Chávez. At the time, Maduro described her as having a ‘fiery character,’ according to Reuters.

The pair did not marry until nearly two decades after first meeting, after Maduro was elected president in 2013.

Fox News’ Emma Bussey contributed to this report.

This post appeared first on FOX NEWS

President Donald Trump is set to huddle with House Republicans on Tuesday morning, days after the U.S. government executed strikes in Venezuela and captured the country’s leader Nicolás Maduro. 

Trump will address GOP lawmakers at the newly renamed Donald J. Trump and John F. Kennedy Memorial Center for the Performing Arts, multiple sources told Fox News Digital. 

A White House schedule released late on Monday said Trump will speak around 10 a.m., and that his remarks will be streamed live.

House Republicans will be at the Trump Kennedy Center for an all-day policy forum Tuesday aimed at discussing their agenda for 2026, according to an email obtained by Fox News Digital.

It comes the day House lawmakers return from a two-week recess for the end-of-year holiday period.

Part of the day’s agenda was meant to include remarks by Trump to rally Republicans around their legislative priorities, but three sources told Fox News Digital they anticipate Venezuela will be a focus of the day as well.

‘My guess is he does 30 minutes on Venezuela and five on policy,’ one House GOP source told Fox News Digital.

Another source told Fox News Digital, ‘I would expect him to give a pretty typical rally-type speech … but who knows.’

That source expressed frustration that Republicans were waiting ‘until we get back to work to strategize.’

Meanwhile, Rep. Mike Haridopolos, R-Fla., also said he expected Trump’s remarks to focus heavily on Venezuela.

‘I think the president is going to walk through not only the justification he had for it, which is the court of law in the United States, but also the fact that, how legitimate is a country if the… Canadians, the [European Union], and the United States, no one recognizes this guy? The only people who recognize him are our enemies,’ the Florida Republican said.

Rep. Wesley Hunt, R-Texas, who is challenging Sen. John Cornyn, R-Texas, for his Senate seat, said he anticipated Trump to discuss November’s elections as well.

Asked what he thought he’d hear from the president, Hunt told Fox News Digital he could see Trump discussing ‘the successes of the administration, how important it’s been, what happened in Caracas a couple of days ago…codifying his agenda, and winning the midterms.’

‘I think we’re going to hear a lot of that,’ Hunt said.

This post appeared first on FOX NEWS

President Donald Trump’s announcement that the United States will temporarily ‘run’ Venezuela following the capture of Nicolás Maduro may prove to be a defining moment for the Western Hemisphere — either a disciplined effort to restore regional stability or the opening chapter of an avoidable, open-ended entanglement.

At his Mar-a-Lago press conference on Saturday, the president stated plainly, ‘We will run the country until such time as we can do a safe, proper and judicious transition.’ He added that members of his national security team standing behind him would oversee the effort and did not rule out ‘boots on the ground.’ Hours later, speaking aboard Air Force One, he sharpened the message further: ‘We’re going to run it, fix it.’

The strategic logic is easy to understand. Venezuela sits atop the world’s largest proven oil reserves and has become a hub for narcotics trafficking, corruption and malign outside influence. The administration’s December 2025 National Security Strategy explicitly embraces what it calls a ‘Trump Corollary’ to the Monroe Doctrine — pledging to deny non-hemispheric competitors such as China, Russia and Iran control over strategically vital assets in the Americas. In that framework, Venezuela is not merely a humanitarian tragedy; it is a test case.

But this is precisely where experience should sober ambition.

The first problem: Who is actually in charge?

A central contradiction now confronts Washington. How does the United States ‘run’ Venezuela when its constitutionally designated vice president, Delcy Rodríguez, has already been sworn in domestically as interim president following Maduro’s removal?

Rodríguez’s claim to authority — backed by Venezuela’s Supreme Tribunal of Justice and regime-loyal institutions — is rejected by Washington as illegitimate. Yet in practical terms, ministries, security forces and regional authorities inside Venezuela remain staffed by officials loyal to the old system. That means the United States is not governing Venezuela in name, law or day-to-day administration — even as presidential rhetoric suggests otherwise.

This disconnect between declared authority and actual control is where post-conflict operations often fail.

Lessons written in blood: Iraq and the cost of improvisation

I learned that lesson firsthand. In 2002 and 2003, I served as a member of then–Defense Secretary Donald Rumsfeld’s Military Analyst Group. We were given extensive access — briefings, travel and candid discussions with officials planning both the Iraq invasion and what would follow.

In early 2003, several of us met with retired officers outlining postwar governance plans. We asked basic but essential questions: Who would secure ministries? How would local governance function? How would electricity, water and fuel distribution be restored? The answers were often vague, more aspirational than operational.

After the invasion, I visited Baghdad and met with Coalition Provisional Authority officials under Ambassador Paul Bremer. Again, the gaps were obvious. We had removed a regime but had not built the machinery needed to prevent the vacuum that follows. 

One decision still echoes: the CPA’s order dissolving Iraq’s security institutions, including the Ministry of Defense. RAND’s official history records that the order was issued with little objection at senior levels, even as misunderstandings were masked by apparent consensus. The result was predictable — security collapsed, insurgency surged and the U.S. presence expanded far beyond its original scope.

Venezuela now risks a similar mistake. Capturing Maduro may prove to be the easy part. Governing what comes next is the hard part — and the part America has too often improvised.

Panama is the wrong analogy

Some have compared Venezuela today to Panama in 1989, when U.S. forces captured Manuel Noriega and quickly installed Guillermo Endara as president. The comparison is tempting — and deeply misleading.

Panama was small, U.S. forces were already present, and a recognized successor government was ready to assume power. Venezuela, by contrast, has 30 million people, no broadly accepted transitional authority and entrenched military-criminal networks embedded throughout the state. What worked in Panama cannot simply be scaled up to Caracas.

‘Not day-to-day governance’— what that really means

Secretary of State Marco Rubio has since clarified that the United States does not intend to govern Venezuela ‘day-to-day.’ That clarification matters — but it raises its own questions. If Washington is not running ministries, courts, budgets or police forces, what does that leadership look like?

In real terms, it appears the administration is signaling a model of indirect control rather than occupation. The primary lever is economic, especially oil.

Venezuela’s political and military elites survive on access to oil revenues. Whoever controls export permissions, sanctions relief, insurance access and dollar-denominated transactions controls the real center of gravity. Conditioning access to those revenues — while freezing assets abroad and coordinating sanctions enforcement with allies — offers Washington leverage over the top of the system without governing the country outright.

That approach amounts to influence without occupation: pressure without American administrators running Caracas.

A narco-state is not a one-man show

There is also a dangerous illusion at work — that removing Maduro dismantles the regime.

Maduro sat at the apex of a narco-state and was indicted in U.S. courts on charges of drug trafficking and narco-terrorism. But he did not act alone. His power rested on a network of generals, intelligence chiefs, judges, energy officials and cartel intermediaries who enriched themselves under the existing system. Many of those figures remain in place today.

They are unlikely to surrender quietly. Some will seek accommodation; others will resist through bureaucratic sabotage, violence or the manipulation of public fear. Without a credible transitional framework anchored in Venezuelan civil society and supported by international legitimacy, the system Maduro built may survive him.

The questions that must be answered — now

If the administration wants to avoid repeating Iraq, it must answer several questions publicly and soon.

What is the legal basis — and limit — of U.S. authority? Who provides immediate security, and under what rules? Which Venezuelan partners will be empowered to lead? What economic plan serves Venezuelans first, not just foreign interests? And how does this mission end?

Once the United States assumes responsibility for ‘running’ another country, it inherits responsibility not only for success but for failure.

The Trump administration can still make Venezuela a model rather than a warning. But doing so will require discipline: clearly defined objectives, credible Venezuelan partners, continuity in security forces, transparent reconstruction tied to humanitarian relief and an exit strategy that is real — not rhetorical.

Venezuela is not Iraq. But history has a way of repeating itself when preparation yields to improvisation.

This post appeared first on FOX NEWS

Sydney, Australia (ABN Newswire) – Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) advised that recent reconnaissance and surface sampling programs have successfully identified a consistent northwest to southeast oriented mineralised corridor at the Mojave Project.

HIGHLIGHTS

– Results from rock chip sampling returns 409g/t Ag confirming high-grade silver mineralisation ~3km from the initial high-grade silver discovery (Sample 258140), 320m southwest of the Desert Antimony Mine (DAM)

– Significant base metal mineralisation confirmed in addition to silver, with samples returning grades up to 4.2% Copper (Cu), 1.5% Lead (Pb), and 1.5% Zinc (Zn), highlighting the polymetallic nature of the system

– Twelve (12) rock chip samples exceeded 30g/t Ag, reinforcing additional precious and base metal potential within the Mojave Project’s North Block

– This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project

This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project. The delineation of a mineralised corridor suggests a strike extent approximately 2.4km westnorthwest of the Hendricks Shaft, and approximately 600m to the east-southeast, extending the mineralised corridor almost 3km from the Silver Prospect. This confirms the presence of a polymetallic quartz vein system, which includes the high-grade sample 258140 collected from a 3cm to 10cm wide vein (Figure 1*). These early results possibly suggest that the Ag-Pb-Zn-Cu mineralisation may reflect the presence of a large-scale hydrothermal system, which could potentially contain valuable concentrations of precious and base metals. Further exploration is required to test this concept.

Rock chip sampling within the Mojave Project’s North Block has returned results of up to 409g/t Ag, with associated base metal values of up to 1.5% Zn and 0.88% Pb, supporting the interpretation of a polymetallic mineralised system and enhancing the prospectivity of the corridor. Additional rock chip sample 258420 returned values up to 117g/t Ag, & 3.1% Cu, also located within the interpreted mineralised corridor located close to a historic adit and workings.

The interpreted mineralised corridor includes the historic Hendricks Shaft, located approximately 2.4km from the initial high-grade silver discovery. A total of 398 rock chip samples have been collected across the North Block with ~260 of these being collected along the mineralised corridor between DAM and up to 5.6km to the southeast.

Rock Chip Sampling Program Details

The recent sampling campaign was designed to test the strike extent of the high-grade silver mineralisation first identified in late 2024. The results (see Table 1) have exceededexpectations, confirming that the mineralised system extends significantly beyond the initial discovery zone (Sample 258140 – Figure 1*).

Key observations from the program include:

– Strike Extension: The mineralised corridor is now interpreted to extend from the Silver Prospect (Sample 258140) to historical trenches and stockpiles (Samples 258184 & 258185) located ~3km to the south-east significantly increasing the strike extent of the exploration target.

– Mineralisation Style: High-grade samples 258184 and 258185, collected from outcropping veins and historic stockpiles, exhibit quartz with gossanous selvages with boxwork textures. These are potential indicators of weathered sulphide-rich polymetallic veins, suggesting fresh sulphides may exist at depth.

– Visual Copper: Sample 258420 (which returned 117g/t Ag & 3.1% Cu) was collected from outcropping mineralisation at historic workings where copper carbonate (i.e. malachite) is visually prevalent (see Figure 3*). This confirms a copper component to the mineralised system.

Next Steps

Locksley will advance this exciting silver and base metal opportunity through a systematic exploration program run in parallel with ongoing activities at DAM and El Campo, comprising:

– Systematic Mapping: Detailed geological mapping between the Silver Prospect and the new south-eastern extension to define the structural geometry and continuity of the trend.

– Petrology and Geochemistry: Submission of samples for petrological interpretation to assist with determining relative timing of mineralisation and geochemical associations across the system.

– Geophysics: Assessment of geophysical survey options, such as Very Low Frequency electromagnetics (VLF-EM), Induced Polarisation (IP), or Electromagnetic (e.g. VTEM) to potentially identify mineralised zones and structures at depth that are not visible at surface.

– Drill Targeting: The goal of this work is to delineate high-priority drill-ready targets along the NW-SE corridor for future testing.

Additional work is planned to improve understanding of the corridor’s structural geometry, enabling more effective drill targeting and delineation of the extent and grade of mineralisation within the North Block.

Kerrie Matthews, Managing Director & CEO, commented:

‘Defining a 3km mineralised trend with surface results of up to 409 g/t silver and 1.5% copper is a highly encouraging outcome. Importantly, this discovery complements our core antimony development strategy and gives exposure as a diversified U.S. critical minerals company, providing shareholders with upside to precious metals, base metals, and strategic minerals within a single, high-quality project area.’

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/R8C037M3

About Locksley Resources Limited:

Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) is an ASX listed explorer focused on critical minerals in the United States of America. The Company is actively advancing exploration across two key assets: the Mojave Project in California, targeting rare earth elements (REEs) and antimony. Locksley Resources aims to generate shareholder value through strategic exploration, discovery and development in this highly prospective mineral region.

Mojave Project

Located in the Mojave Desert, California, the Mojave Project comprises over 250 claims across two contiguous prospect areas, namely, the North Block/Northeast Block and the El Campo Prospect. The North Block directly abuts claims held by MP Materials, while El Campo lies along strike of the Mountain Pass Mine and is enveloped by MP Materials’ claims, highlighting the strong geological continuity and exploration potential of the project area.

In addition to rare earths, the Mojave Project hosts the historic ‘Desert Antimony Mine’, which last operated in 1937. Despite the United States currently having no domestic antimony production, demand for the metal remains high due to its essential role in defense systems, semiconductors, and metal alloys. With significant surface sample results, the Desert Mine prospect represents one of the highest-grade known antimony occurrences in the U.S.

Locksley’s North American position is further strengthened by rising geopolitical urgency to diversify supply chains away from China, the global leader in both REE & antimony production. With its maiden drilling program planned, the Mojave Project is uniquely positioned to align with U.S. strategic objectives around critical mineral independence and economic security.

Tottenham Project

Locksley’s Australian portfolio comprises the advanced Tottenham Copper-Gold Project in New South Wales, focused on VMS-style mineralisation

Source:
Locksley Resources Limited

Contact:
Kerrie Matthews
Chief Executive Officer
Locksley Resources Limited
T: +61 8 9481 0389
Kerrie@locksleyresources.com.au

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com

Today’s pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry’s major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2025, 46 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 50 such approvals in 2024.

Big pharma largely steals the show when people discuss pharmaceutical companies, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Read on to learn more about their activities this year.

1. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 211.45 percent
Market cap: US$263.08 million
Share price: US$4.08

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein. Belapectin has been granted fast-track designation by the FDA.

In 2025, Galectin Therapeutics reported positive topline data from its Phase 2b/3 trial evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension. The results demonstrated that belapectin significantly reduced the development of new esophageal varices and stabilized liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

Galectin is currently designing its pivotal Phase 3 study intended to support a formal new drug application. Based on a December 2025 response from the FDA, the company said it believes it has achieved alignment with the agency on the patient population for its upcoming registration-level trials.

2. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

In mid-May 2025, CytomX’s share price shot up significantly after the company provided its Q1 business update and closed on a US$100 million underwritten offering of common stock.

In the update, CytomX included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer. The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. In its Q3 update, CytomX reported it plans to initiate a Phase 1b study of CX-2051 in combination with bevacizumab to treat colorectal cancer, also expected in the first quarter of the new year.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) Keytruda in patients with metastatic melanoma. The company released initial translational data in November.

3. Eton Pharmaceuticals (NASDAQ:ETON)

Year-to-date gain: 25.37 percent
Market cap: US$450.53 million
Share price: US$16.80

Eton Pharmaceuticals is a high-growth pharmaceutical company developing treatments for rare diseases. Headquartered in Deer Park, Illinois, the company has successfully transitioned from a development-stage firm into a commercially focused entity with a diversified portfolio of orphan drugs.

2025 included the successful launch of KHINDIVI, the first FDA-approved oral solution formulation of hydrocortisone, in June. KHINDIVI was approved in May for pediatric patients five and older with adrenocortical insufficiency. The company is looking to expand the indication to younger patients with a revised formulation, and a bioequivalence study is expected to begin in early 2026.

The year also included high-performing relaunches of acquired assets Increlex, which treats a rare condition in which a child’s body does not produce enough growth factor-1, and the zinc therapy Galzin, a maintenance treatment for Wilson disease.

As of December, its portfolio included eight commercial products and five in its pipeline. The FDA is reviewing its new drug application for ET-600, with a decision scheduled for late February.

4. Fennec Pharmaceuticals (NASDAQ:FENC)

Year-to-date gain: 20.91 percent
Market cap: US$262.54 million
Share price: US$7.69

Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on preventing ototoxicity, meaning permanent hearing loss, in pediatric cancer patients undergoing cisplatin-based chemotherapy.

The company’s sole commercial product, Pedmark, is the first and only FDA-approved therapy specifically indicated to reduce the risk of hearing loss associated with cisplatin in patients one month of age and older with non-metastatic solid tumors.

Fennec experienced a pivotal year in 2025, marked by record revenue growth, entry into international markets and the elimination of corporate debt.

Additionally, data from a Phase 2/3 clinical study in Japan showed a significant reduction in the percentage of patients who experienced hearing loss, setting the stage for a 2026 global registration.

The company also began exploring its first major expansion into the adult cancer market through a new trial in metastatic testicular cancer.

5. Zevra Therapeutics (NASDAQ:ZVRA)

Year-to-date gain: 5.25 percent
Market cap: US$496.54 million
Share price: US$8.82

Zevra Therapeutics is a commercial-stage rare disease company that utilizes data-driven strategies to develop and commercialize transformational therapies for ultra-rare conditions.

Formerly known as KemPharm, the company rebranded in 2023 to reflect its evolution into a fully integrated pharmaceutical entity with a focus on high-unmet-need pediatric and metabolic disorders.

At the end of December, Zevra executed a strategic distribution agreement with Uniphar to provide its flagship product, Miplyffa, to patients outside of the US and Europe, broadening the drug’s global footprint. Miplyffa was approved by the FDA in 2024, and is indicated as a treatment for Niemann-Pick disease type C administered in combination with miglustat.

This announcement followed a strong Q3, in which the company reported a 605 percent year-over-year revenue increase, largely driven by the early success of Miplyffa.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investor Insight

Juggernaut Exploration is an early-stage explorer and project generator with a compelling investment story, focused on unlocking high-grade precious and base metal discoveries in the prolific Golden Triangle of northwestern British Columbia.

Overview

Juggernaut Exploration(TSXV:JUGR,OTCQB:JUGRF,FSE:4JE) is a precious metals explorer focused on northwestern British Columbia’s Golden Triangle, a globally recognized district for world-class porphyry, VMS, and high-grade gold systems. The company operates in a geopolitically stable jurisdiction with excellent infrastructure, adjacent to Newmont’s Galore Creek project and in proximity to major road and airstrip developments.

The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of British Columbia’s most prolific mineral belt.

The company’s current strategy focuses on aggressive exploration at its flagship Big One project, where the rapid abatement of glacial cover led to the discovery of over 200 mineralized veins in a matter of days. The scale of the system, coupled with strong geophysical and geochemical signatures, points to a significant buried porphyry system.

Backed by world-renowned geologist Dr. Quinton Hennigh, Juggernaut was founded by the team behind Goliath Resources, which returned 2,400 percent to early investors in just 20 months.

Company Highlights

  • The Big One property has uncovered a 15-km gold-rich porphyry system, described as a “highway of gold,” adjacent to Newmont’s $100 billion Galore Creek project.
  • Founded by the team behind Goliath Resources, which returned 3,400 percent to early investors in just 20 months. World-renowned geologist Dr. Quinton Hennigh supports Juggernaut.
  • Crescat Capital is a cornerstone investor, holding a 19.99 percent stake and providing both financial and technical backing.
  • The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of the Golden Triangle in British Columbia.
  • With $12.5 million recently raised, the 2025 field season is fully funded. The upcoming campaign aims to scale and define the scope of the porphyry system discovered in just five days of boots-on-the-ground work.
  • 5-Year Drill Permit Secured: A valid 5-year drill permit is in place for the Big One Property in British Columbia’s Golden Triangle, in good standing through March 31, 2031.
  • 2026 Inaugural Drill Program: The company is planning a fully funded drill program to test multiple gold-rich, shear-hosted vein targets identified at surface within the newly discovered, district-scale Eldorado System and Gold Swarm discoveries, targeting depth extensions in the third dimension.
  • Over 70 percent of the company’s shares are held by management, insiders and accredited investors. The company is debt-free.

Key Projects

Big One

The Big One project is Juggernaut’s flagship asset located in the heart of British Columbia’s Golden Triangle. The property spans 36,989 hectares of world-class geological terrain, with 95 percent of its remaining unexplored.

The project benefits from rapid glacial and snowpack abatement, which has recently exposed a vast mineralized system previously hidden under ice. This includes the newly identified Eldorado porphyry system, a high-grade, multi-kilometer corridor with grades reaching up to 79.01 grams per ton (g/t) gold and 3,157 g/t silver. More than 200 quartz-sulphide veins, containing semi-massive to massive chalcopyrite, sphalerite and galena, have been identified within a 4 km x 1 km alteration footprint, with coincident geophysical anomalies suggesting the presence of a large, buried mineralizing system at depth.

The Big One project qualifies for the Critical Mineral Exploration Tax Credit and is strategically located adjacent to key infrastructure, including the Scud airstrip and a new $45 million government-funded road within 12 km of the site.

In 2025, Juggernaut Exploration received a 5-year drill permit for the Big One property. The permit is in good standing until March 31, 2031. The company is planning a drill program targeting several extensive gold-rich shear-hosted veins confirmed on surface in the newly discovered district-scale Eldorado System and Gold Swarm discoveries. These strong drill targets are planned to be tested in the third dimension during the fully-funded inaugural drill program in 2026.

Newly discovered drill ready El Dorado System

Midas

The Midas property covers 20,803 hectares in a geologically favorable setting for volcanogenic massive sulphide (VHMS) deposits, particularly those resembling the high-grade Eskay Creek system. Drilling at the Kokomo zone has intercepted significant VHMS-style mineralization, including standout results such as 8.27 g/t gold equivalent over 11.03 meters (MD-24-47) and 6.85 g/t gold over 9 meters (MD-18-08). The mineralized zone remains open to the north, and the company plans to step out aggressively with additional drilling.

Midas is considered a strong near-term value generator with potential for scale through further discovery.

Bingo

The Bingo property, although smaller in footprint at 1,008 hectares, is located in a structurally favorable setting for shear-hosted gold systems. The project features a 700-meter x 400-meter mineralized zone characterized by consistent sulphide mineralization. Sampling has confirmed an average mineralized width of 7 meters with grades averaging 5.67 g/t gold equivalent. The presence of strong K-spar alteration in the northeast quadrant of the property suggests proximity to a porphyry feeder system, making Bingo a compelling target for both high-grade, shear-hosted and porphyry-style exploration.

Management Team

Manuele (Lele) Lazzarotto – President and Chief Operating Officer (COO)

Manual Lazzarotto, Ph.D., has over a decade of experience in the mineral exploration industry, taking projects from inception to defined deposits. He has extensive experience in volcanogenic massive sulphide deposits and gold systems in Canada. Most recently, Lazzarotto has acted as chief geologist, instrumental in the discovery of Goliath Resources’ Surebet Discovery from 2019 to 2025. He holds a BSc and an MSc in Earth Sciences from ETH Zurich, Switzerland, and a PhD in Metamorphic Petrology from the University of Calgary, Canada.

Dan Stuart – CEO and Director

Dan Stuart has over 30 years of experience in capital markets, having raised more than $500 million for natural resource companies. He is a founding member and financier of several private mineral syndicates, including the J2 Syndicate behind Goliath Resources. Stuart is recognized for his investor acumen and has established strong institutional relationships across North America, Europe, Asia, and the Middle East. Under his leadership, Juggernaut secured cornerstone funding from Crescat Capital and Dr. Quinton Hennigh while simultaneously building a platform for rapid discovery-driven growth.

Jim McCrea – Director

Jim McCrea brings 25 years of exploration and resource estimation experience. Notably, he worked on orebody modeling and resource estimation at Cumberland Resources, which was acquired by Agnico Eagle for $710 million. His deep expertise in geology and modeling helps guide exploration targeting and resource development.

William Jung – Director and CFO

A former chartered accountant with over 35 years of experience in finance, William Jung has managed several publicly listed companies on the TSX. His oversight ensures financial discipline, compliance, and strategic capital allocation.

Peter Bryant – Director

Peter Bryant is a seasoned international investment banker with 45 years of experience, including senior roles at Standard Chartered Group, Hill Samuel Group, and Guinness Mahon Holdings in London. His presence brings strong governance and capital markets insights to the board.

Chris Verrico – Director

Chris Verrico has over two decades of experience managing mineral exploration and infrastructure projects in remote northern regions, including British Columbia, Yukon and Nunavut. His knowledge of field operations and community engagement is critical to project execution.

Bill Chornobay – Program Manager

Bill Chornobay has over 30 years of experience in mineral exploration and has been directly involved in discoveries resulting in more than $1 billion in value. He played a pivotal role in the Surebet discovery for Goliath Resources and now leads on-ground execution at Juggernaut.

Dr. Quinton Hennigh – Technical Advisor

A globally respected exploration geologist, Dr. Quinton Hennigh has over 30 years of experience with major mining companies, including Homestake, Newcrest and Newmont. He is currently the chairman of Novo Resources and serves as a technical advisor to Crescat Capital. His guidance has helped validate and shape the exploration strategy at Juggernaut.

Dr. Manuele Lazzarotto – Senior Consulting Geologist

Dr. Manuele Lazzarotto has eight years of experience advancing early-stage exploration projects into defined resources, particularly in VMS and gold systems. He played a critical technical role in the Surebet discovery and brings valuable geological and structural insight to Juggernaut’s targeting approach.

This post appeared first on investingnews.com

David Morgan, publisher of the Morgan Report, weighs in on silver’s record-setting price rise and what could be next for the white metal heading into 2026.

‘We’re still in price discovery. I truly believe that,’ he said.

‘What the true price of silver is in US dollars, Canadian dollars, I do not know. I think it’s north of $100 in US dollar terms, but it could be much higher than that.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Perth, Australia (ABN Newswire) – Altech Batteries Ltd (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) announced that binding conditional funding approval in the amount of 46.11 million Euro has now been granted for the CERENERGY(R) Sodium-Chloride Solid-State battery project in Saxony, Germany. The grant approval materially derisks project funding and supports progression toward construction of the planned 120 MWh CERENERGY(R) battery manufacturing facility in Saxony, Germany.

Highlights

– Altech Batteries GmbH’s CERENERGY(R) battery project has received conditional binding funding approval under Germany’s federal ‘STARK’ economic development program.

– The approval relates to a grant covering approximately 30% of eligible project CAPEX, with funding of up to EUR46.11M.

– The funding commitment is conditional on achieving full project financial close by 30 June 2026 and parliamentary approval of funds under Germany’s 2026 Federal Budget.

Conditional Binding Funding Commitment

The funding is being provided as part of the federal STARK program, which is supported by the Federal Ministry for Economic Affairs and Energy in cooperation with the EU. The aim of this program is to lead regions undergoing structural change into an ecologically, economically and socially sustainable future.

With the approval of the funding, the project has successfully completed the second and decisive stage of the approval process. The funding covers approximately 30% of the eligible investment costs and represents a significant milestone for the construction of the planned 120 MWh CERENERGY(R) battery factory in Germany.

This decision underscores the importance of the innovative CERENERGY(R) technology, which is being developed in collaboration with the Fraunhofer Society. The Sodium-Chloride Solid-State battery offers a safe, sustainable and strategically independent alternative to lithium-ion batteries and is expected to play an important role in future stationary energy storage solutions – especially for the European market.

Mr Daniel Raihani, Managing Director & Chief Executive Officer, commented ‘Securing conditional binding funding approval of up to EUR46.11 million under Germany’s STARK program is a major milestone for the CERENERGY(R) project. The support reflects the strategic importance of establishing advanced, nonlithium energy storage manufacturing capability in Europe and recognises the technical progress achieved to date in collaboration with Fraunhofer IKTS.

‘Importantly, the grant materially de-risks the project’s capital structure by covering approximately 30% of eligible investment costs and provides a strong foundation as we progress toward full project financing and construction of the planned 120 MWh production facility in Saxony, Germany.

‘We remain focused on completing financial close by mid-2026 and advancing the CERENERGY(R) technology toward commercial deployment to support long-duration, safe and sustainable stationary energy storage solutions for the European market’.

As is customary for projects of this size, the funding commitment is subject to final financial close of the CERENERGY(R) battery project by June 2026 and budgetary approval of the funds in the 2026 federal budget.

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/918BT5H8

About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS (‘Fraunhofer’) to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech’s land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

Source:
Altech Batteries Ltd

Contact:
Daniel Raihani
Managing Director
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

Martin Stein
Chief Financial Officer
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com